Brief: HDL Therapeutics To Go Public In Merger With Swiftmerge Acquisition Corp.

Aleanna

11/08/2023 18:57

Aug 11 (Reuters) - Swiftmerge Acquisition Corp  IVCP.O :
    * HDL THERAPEUTICS TO GO PUBLIC IN MERGER WITH SWIFTMERGE
ACQUISITION CORP.
    * SWIFTMERGE ACQUISITION CORP- $480 MILLION BUSINESS
COMBINATION
TO ACCELERATE COMMERCIALIZATION OF AN INNOVATIVE FDA-APPROVED
CARDIOVASCULAR DISEASE TREATMENT
    * SWIFTMERGE ACQUISITION CORP- SWIFTMERGE WILL CHANGE ITS
NAME TO
HDL THERAPEUTICS, INC UPON CLOSE OF DEAL
    * SWIFTMERGE ACQUISITION CORP- ANTICIPATED THAT HDL
THERAPEUTICS
WILL TRADE ON NASDAQ WITH TICKER SYMBOL "HDLT"
    * SWIFTMERGE ACQUISITION CORP - COMBINED COMPANY EXPECTS TO
RECEIVE ABOUT $104 MILLION IN GROSS PROCEEDS
    * SWIFTMERGE ACQUISITION CORP- MICHAEL MATIN WILL BE
CHAIRMAN OF
BOARD AND CHIEF EXECUTIVE OFFICER OF COMBINED COMPANY
    * SWIFTMERGE ACQUISITION CORP- BUSINESS COMBINATION BETWEEN
HDL
THERAPEUTICS AND SWIFTMERGE VALUES COMBINED COMPANY AT
APPROXIMATELY $480 MILLION
    * SWIFTMERGE ACQUISITION CORP - SWIFTMERGE'S SPONSOR HAS
ALSO
AGREED NOT TO SELL ITS FOUNDER EQUITY FOR SIX MONTHS AFTER
CLOSING

Source text for Eikon:  ID:nBw4mxsHVa 
Further company coverage:  IVCP.O 

 ((Reuters.Briefs@thomsonreuters.com;))